Dimensional Fund Advisors LP Has $1.07 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Dimensional Fund Advisors LP lowered its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 82.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,924 shares of the company's stock after selling 271,156 shares during the quarter. Dimensional Fund Advisors LP owned 0.07% of Viridian Therapeutics worth $1,072,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $26,000. Summit Investment Advisors Inc. raised its position in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after purchasing an additional 1,516 shares during the period. AlphaQuest LLC lifted its holdings in shares of Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after purchasing an additional 1,519 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Viridian Therapeutics by 19.5% in the fourth quarter. Arizona State Retirement System now owns 16,596 shares of the company's stock worth $318,000 after buying an additional 2,708 shares during the period. Finally, Corebridge Financial Inc. increased its position in shares of Viridian Therapeutics by 8.6% in the fourth quarter. Corebridge Financial Inc. now owns 36,336 shares of the company's stock worth $697,000 after acquiring an additional 2,878 shares in the last quarter.

Viridian Therapeutics Stock Down 1.2%

VRDN stock opened at $13.66 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The company has a 50-day moving average of $13.25 and a two-hundred day moving average of $16.99. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -3.17 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics's quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC reiterated a "buy" rating and set a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday. Royal Bank of Canada decreased their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group lowered their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JMP Securities dropped their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.